David Shaw’s Cardio Diagnostics CDIO Stock Holding History

David Shaw’s Portfolio CDIO Stock Details CDIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-669	Closed	-$22.3K	–	4476
2022 Q4	$22.3K	Sell	669 -5,999	-90%	-$648K	﹤0.01%	4512
2022 Q3	$2.01M	Hold	6,668	–	–	﹤0.01%	3008
2022 Q2	$1.99M	Hold	6,668	–	–	﹤0.01%	3084
2022 Q1	$1.98M	Buy	+6,668	New	+$1.97M	﹤0.01%	3317

Other funds holding CDIO

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

CSC

Caldwell Sutter Capital Sausalito, California $265M AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

David Shaw's CDIO Position: Q1 2023 in Review

David Shaw sold out of Cardio Diagnostics (CDIO) in Q1 2023, closing a stake of 669 shares — an estimated $22.3K sold.

David Shaw first reported a position in CDIO in Q1 2022 and held it in 4 quarters. The position peaked at $2.01M in Q3 2022. 11 funds tracked by Wall St. Rank hold CDIO as of Q1 2023.

David Shaw reported no remaining Cardio Diagnostics position as of Q1 2023 after selling out during the quarter.
David Shaw sold 669 Cardio Diagnostics shares in Q1 2023, an estimated $22.3K.
David Shaw first reported a position in Cardio Diagnostics in Q1 2022 and held it in 4 quarters.
David Shaw's Cardio Diagnostics position peaked at $2.01M in Q3 2022.
11 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q1 2023.

Based on D.E. Shaw & Co's 13F filing for Q1 2023, filed 15 May 2023.